JP7242553B2 - 基質の調製のための方法及び組成物 - Google Patents
基質の調製のための方法及び組成物 Download PDFInfo
- Publication number
- JP7242553B2 JP7242553B2 JP2019562223A JP2019562223A JP7242553B2 JP 7242553 B2 JP7242553 B2 JP 7242553B2 JP 2019562223 A JP2019562223 A JP 2019562223A JP 2019562223 A JP2019562223 A JP 2019562223A JP 7242553 B2 JP7242553 B2 JP 7242553B2
- Authority
- JP
- Japan
- Prior art keywords
- collagen
- matrix
- kit
- clauses
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 224
- 239000000203 mixture Substances 0.000 title claims description 123
- 239000000758 substrate Substances 0.000 title description 15
- 238000002360 preparation method Methods 0.000 title description 4
- 102000008186 Collagen Human genes 0.000 claims description 551
- 229920001436 collagen Polymers 0.000 claims description 551
- 108010035532 Collagen Proteins 0.000 claims description 550
- 239000007853 buffer solution Substances 0.000 claims description 154
- 239000011159 matrix material Substances 0.000 claims description 128
- 239000000243 solution Substances 0.000 claims description 124
- 238000002156 mixing Methods 0.000 claims description 55
- 230000005855 radiation Effects 0.000 claims description 38
- 230000000379 polymerizing effect Effects 0.000 claims description 36
- 241000700605 Viruses Species 0.000 claims description 18
- 238000011146 sterile filtration Methods 0.000 claims description 18
- 239000007943 implant Substances 0.000 claims description 16
- 230000001954 sterilising effect Effects 0.000 claims description 16
- 238000004659 sterilization and disinfection Methods 0.000 claims description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- 230000002439 hemostatic effect Effects 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000011777 magnesium Substances 0.000 claims description 7
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 7
- 229910001437 manganese ion Inorganic materials 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 238000010894 electron beam technology Methods 0.000 claims description 6
- 238000011100 viral filtration Methods 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 120
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 54
- 238000006116 polymerization reaction Methods 0.000 description 49
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 48
- 210000001519 tissue Anatomy 0.000 description 37
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 25
- 239000008103 glucose Substances 0.000 description 25
- 229910001629 magnesium chloride Inorganic materials 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 239000002253 acid Substances 0.000 description 18
- 238000011160 research Methods 0.000 description 16
- 238000003860 storage Methods 0.000 description 16
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 14
- 239000000356 contaminant Substances 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 238000001338 self-assembly Methods 0.000 description 10
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 7
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 7
- 235000015165 citric acid Nutrition 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 230000009977 dual effect Effects 0.000 description 7
- 235000019253 formic acid Nutrition 0.000 description 7
- 235000011167 hydrochloric acid Nutrition 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 235000011054 acetic acid Nutrition 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 238000007876 drug discovery Methods 0.000 description 6
- 230000009969 flowable effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 231100000041 toxicology testing Toxicity 0.000 description 6
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 5
- 239000007836 KH2PO4 Substances 0.000 description 5
- 206010070863 Toxicity to various agents Diseases 0.000 description 5
- 108010045569 atelocollagen Proteins 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 5
- 235000019796 monopotassium phosphate Nutrition 0.000 description 5
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 4
- 229920001222 biopolymer Polymers 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000003929 acidic solution Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000008366 buffered solution Substances 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 235000019800 disodium phosphate Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000010915 one-step procedure Methods 0.000 description 3
- 210000004876 tela submucosa Anatomy 0.000 description 3
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 108010009711 Phalloidine Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003534 oscillatory effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000007838 tissue remodeling Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 description 1
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000728679 Homo sapiens Apoptosis-associated speck-like protein containing a CARD Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035557 fibrillogenesis Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- -1 for example Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 210000005033 mesothelial cell Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000001074 muscle attachment cell Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000005009 osteogenic cell Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0029—Radiation
- A61L2/0047—Ultraviolet radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452564P | 2017-01-31 | 2017-01-31 | |
| US62/452,564 | 2017-01-31 | ||
| PCT/US2018/016069 WO2018144496A1 (en) | 2017-01-31 | 2018-01-31 | Methods and compositions for matrix preparation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505474A JP2020505474A (ja) | 2020-02-20 |
| JP2020505474A5 JP2020505474A5 (cg-RX-API-DMAC7.html) | 2021-03-11 |
| JP7242553B2 true JP7242553B2 (ja) | 2023-03-20 |
Family
ID=63041072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019562223A Active JP7242553B2 (ja) | 2017-01-31 | 2018-01-31 | 基質の調製のための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12280176B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3576775B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7242553B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110446500B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3052266A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3040675T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018144496A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9878071B2 (en) | 2013-10-16 | 2018-01-30 | Purdue Research Foundation | Collagen compositions and methods of use |
| EP3185922B1 (en) | 2014-08-27 | 2025-04-02 | Purdue Research Foundation | Collagen-based therapeutic delivery systems |
| WO2016172365A1 (en) | 2015-04-21 | 2016-10-27 | Purdue Research Foundation Office Of Technology Commercialization | Cell-collagen-silica composites and methods of making and using the same |
| JP7242553B2 (ja) | 2017-01-31 | 2023-03-20 | ジェニフィス，インコーポレイテッド | 基質の調製のための方法及び組成物 |
| WO2018200750A1 (en) | 2017-04-25 | 2018-11-01 | Purdue Research Foundation | 3-dimensional (3d) tissue-engineered muscle for tissue restoration |
| US11808760B1 (en) * | 2019-02-14 | 2023-11-07 | Curi Bio, Inc. | System and methods for in vitro structural toxicity testing |
| CA3168904A1 (en) * | 2020-01-27 | 2021-08-05 | Geniphys, Inc. | Biologic filler for restoring and regenerating tissue |
| CN116999619B (zh) * | 2023-08-03 | 2024-03-19 | 浙江崇山生物制品有限公司 | 一种软骨用胶原凝胶及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001511431A (ja) | 1997-07-28 | 2001-08-14 | フィブロジェン， インコーポレイテッド | Ｉ型およびｉｉｉ型コラーゲン接着剤組成物 |
| US20080268052A1 (en) | 2006-09-21 | 2008-10-30 | Voytik-Harbin Sherry L | Collagen preparation and method of isolation |
| JP2011525197A (ja) | 2009-07-27 | 2011-09-15 | 國立成功大學 | 高純度コラーゲンの調製 |
| US20120297550A1 (en) | 2007-06-12 | 2012-11-29 | Musculoskeletal Transplant Foundation | Process for sterilizing acellular soft tissue with irradiation |
Family Cites Families (165)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3949073A (en) | 1974-11-18 | 1976-04-06 | The Board Of Trustees Of Leland Stanford Junior University | Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution |
| US4233360A (en) | 1975-10-22 | 1980-11-11 | Collagen Corporation | Non-antigenic collagen and articles of manufacture |
| US4439521A (en) | 1981-10-21 | 1984-03-27 | Ontario Cancer Institute | Method for producing self-reproducing mammalian pancreatic islet-like structures |
| US4582640A (en) | 1982-03-08 | 1986-04-15 | Collagen Corporation | Injectable cross-linked collagen implant material |
| US4544516A (en) | 1982-07-28 | 1985-10-01 | Battelle Development Corporation | Collagen orientation |
| US4801299A (en) | 1983-06-10 | 1989-01-31 | University Patents, Inc. | Body implants of extracellular matrix and means and methods of making and using such implants |
| IL74715A0 (en) | 1984-03-27 | 1985-06-30 | Univ New Jersey Med | Biodegradable matrix and methods for producing same |
| US4789663A (en) | 1984-07-06 | 1988-12-06 | Collagen Corporation | Methods of bone repair using collagen |
| US4743552A (en) | 1984-09-26 | 1988-05-10 | Sloan-Kettering Institute For Cancer Research | Method for growth in tissue culture of normal colonic epithelial cells and method for determination of preneoplastic color cells |
| US4600533A (en) | 1984-12-24 | 1986-07-15 | Collagen Corporation | Collagen membranes for medical use |
| US4829000A (en) | 1985-08-30 | 1989-05-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Reconstituted basement membrane complex with biological activity |
| US5863531A (en) | 1986-04-18 | 1999-01-26 | Advanced Tissue Sciences, Inc. | In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework |
| US5266480A (en) | 1986-04-18 | 1993-11-30 | Advanced Tissue Sciences, Inc. | Three-dimensional skin culture system |
| US5032508A (en) | 1988-09-08 | 1991-07-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
| GB8618374D0 (en) | 1986-07-28 | 1986-09-03 | Hsc Res Dev Corp | Biological vascular prostheses |
| JPH0774239B2 (ja) | 1986-09-04 | 1995-08-09 | 新田ゼラチン株式会社 | 細胞培養用高ゲル強度酸可溶性コラーゲンの製法 |
| US5604106A (en) | 1987-06-05 | 1997-02-18 | Us Commerce | Method for detecting carcinoma |
| US5067961A (en) * | 1988-02-18 | 1991-11-26 | Autogenesis Technologies, Inc. | Non-biodegradable two phase corneal implant and method for preparing same |
| JPH0728730B2 (ja) | 1988-03-27 | 1995-04-05 | 新技術事業団 | 擬膵島および拡散チャンバー型人工膵臟 |
| US4902508A (en) | 1988-07-11 | 1990-02-20 | Purdue Research Foundation | Tissue graft composition |
| US4956178A (en) | 1988-07-11 | 1990-09-11 | Purdue Research Foundation | Tissue graft composition |
| US4912057A (en) | 1989-06-13 | 1990-03-27 | Cancer Diagnostics, Inc. | Cell chamber for chemotaxis assay |
| US5336616A (en) | 1990-09-12 | 1994-08-09 | Lifecell Corporation | Method for processing and preserving collagen-based tissues for transplantation |
| US5163955A (en) | 1991-01-24 | 1992-11-17 | Autogenics | Rapid assembly, concentric mating stent, tissue heart valve with enhanced clamping and tissue alignment |
| WO1992015676A1 (en) | 1991-03-08 | 1992-09-17 | The Salk Institute For Biological Studies | Somatic cell gene therapy |
| ES2179821T3 (es) | 1991-06-24 | 2003-02-01 | Hcell Technology Inc | Celulas pancreaticas secretoras de hormonas y mantenimiento en cultivo a largo plazo. |
| FR2678624A1 (fr) | 1991-07-04 | 1993-01-08 | Coletica | Utilisation de la peau non pigmentee de poisson, en particulier de poisson plat comme nouvelle source industrielle de collagene, procede d'extraction, collagene et biomateriau ainsi obtenus. |
| US5281422A (en) | 1991-09-24 | 1994-01-25 | Purdue Research Foundation | Graft for promoting autogenous tissue growth |
| US5204382A (en) | 1992-02-28 | 1993-04-20 | Collagen Corporation | Injectable ceramic compositions and methods for their preparation and use |
| US5428022A (en) | 1992-07-29 | 1995-06-27 | Collagen Corporation | Composition of low type III content human placental collagen |
| US5478739A (en) | 1992-10-23 | 1995-12-26 | Advanced Tissue Sciences, Inc. | Three-dimensional stromal cell and tissue culture system |
| US5641518A (en) | 1992-11-13 | 1997-06-24 | Purdue Research Foundation | Method of repairing bone tissue |
| US5275826A (en) | 1992-11-13 | 1994-01-04 | Purdue Research Foundation | Fluidized intestinal submucosa and its use as an injectable tissue graft |
| US5352463A (en) | 1992-11-13 | 1994-10-04 | Badylak Steven F | Tissue graft for surgical reconstruction of a collagenous meniscus and method therefor |
| US5510263A (en) | 1993-04-05 | 1996-04-23 | Desmos, Inc. | Growth of pancreatic islet-like cell clusters |
| US5460962A (en) | 1994-01-04 | 1995-10-24 | Organogenesis Inc. | Peracetic acid sterilization of collagen or collagenous tissue |
| JPH0789564B2 (ja) | 1994-04-12 | 1995-09-27 | 株式会社東芝 | 半導体装置の製造方法 |
| US6475232B1 (en) | 1996-12-10 | 2002-11-05 | Purdue Research Foundation | Stent with reduced thrombogenicity |
| US5709934A (en) | 1994-11-22 | 1998-01-20 | Tissue Engineering, Inc. | Bipolymer foams having extracellular matrix particulates |
| US6485723B1 (en) | 1995-02-10 | 2002-11-26 | Purdue Research Foundation | Enhanced submucosal tissue graft constructs |
| US5695998A (en) | 1995-02-10 | 1997-12-09 | Purdue Research Foundation | Submucosa as a growth substrate for islet cells |
| US5916790A (en) | 1995-03-03 | 1999-06-29 | Metabolex, Inc. | Encapsulation compositions, and methods |
| US5554389A (en) | 1995-04-07 | 1996-09-10 | Purdue Research Foundation | Urinary bladder submucosa derived tissue graft |
| US5711969A (en) | 1995-04-07 | 1998-01-27 | Purdue Research Foundation | Large area submucosal tissue graft constructs |
| US5776193A (en) | 1995-10-16 | 1998-07-07 | Orquest, Inc. | Bone grafting matrix |
| AU736255B2 (en) | 1995-10-25 | 2001-07-26 | Shire Human Genetic Therapies, Inc. | Hybrid matrix implants and explants |
| US6419920B1 (en) | 1995-10-25 | 2002-07-16 | Trans Karyotic Therapies, Inc. | Hybrid matrix implants and explants |
| ATE258810T1 (de) | 1995-11-09 | 2004-02-15 | Univ Massachusetts | Wiederherstellung der gewebeoberfläche mit zusammensetzungen aus hydrogel-zellen |
| EP0953040A4 (en) | 1996-04-26 | 2001-12-12 | Univ Case Western Reserve | REGENERATION OF THE SKIN USING MESENCHYMAL STEM CELLS |
| US6171344B1 (en) | 1996-08-16 | 2001-01-09 | Children's Medical Center Corporation | Bladder submucosa seeded with cells for tissue reconstruction |
| ATE237371T1 (de) | 1996-08-16 | 2003-05-15 | Childrens Medical Center | Blasenmukosa mit zellen für die rekonstruktion von geweben |
| US6666892B2 (en) | 1996-08-23 | 2003-12-23 | Cook Biotech Incorporated | Multi-formed collagenous biomaterial medical device |
| EP1955721B1 (en) | 1996-08-23 | 2014-10-29 | Cook Biotech, Inc. | Collagen-based graft prosthesis |
| JP4572009B2 (ja) | 1996-09-16 | 2010-10-27 | パーデュー・リサーチ・ファウンデーション | 神経学的組織を修復する組成物および方法 |
| WO1998025546A1 (en) | 1996-12-10 | 1998-06-18 | Cook Biotech, Inc. | Tubular grafts from purified submucosa |
| AU720274B2 (en) | 1996-12-10 | 2000-05-25 | Purdue Research Foundation | Stomach submucosa derived tissue graft |
| AU728949C (en) | 1996-12-10 | 2007-03-29 | Purdue Research Foundation | Submucosa extracts |
| CA2274033C (en) | 1996-12-10 | 2010-05-11 | Purdue Research Foundation | Biomaterial derived from vertebrate liver tissue |
| EP0929338A1 (en) | 1997-05-23 | 1999-07-21 | Biosense, Inc. | Catheter with oblique lumen |
| US6248587B1 (en) | 1997-11-26 | 2001-06-19 | University Of Southern Cailfornia | Method for promoting mesenchymal stem and lineage-specific cell proliferation |
| AU743808B2 (en) | 1998-02-27 | 2002-02-07 | Purdue Research Foundation | Submucosa gel compositions |
| DE19812713A1 (de) | 1998-03-24 | 1999-09-30 | Merck Patent Gmbh | Verfahren zur Herstellung von mineralisierten Kollagenfibrillen und deren Verwendung als Knochenersatzwerkstoff |
| CA2342589A1 (en) | 1998-09-11 | 2000-03-23 | Purdue Research Foundation | Enhanced submucosal tissue graft constructs |
| ES2402739T3 (es) | 1998-11-19 | 2013-05-08 | Organogenesis Inc. | Constructos tisulares modificados por bioingeniería y métodos para producirlos y utilizarlos |
| US6918396B1 (en) | 1998-12-01 | 2005-07-19 | Purdue Research Foundation | Method for vocal cord reconstruction |
| US7396809B1 (en) | 1999-02-10 | 2008-07-08 | Curis, Inc. | Methods and reagents for treating glucose metabolic disorders |
| US7615373B2 (en) | 1999-02-25 | 2009-11-10 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen and tissue engineering |
| US6592623B1 (en) | 1999-08-31 | 2003-07-15 | Virginia Commonwealth University Intellectual Property Foundation | Engineered muscle |
| US20050153442A1 (en) | 1999-03-10 | 2005-07-14 | Adam Katz | Adipose-derived stem cells and lattices |
| AU4351000A (en) | 1999-04-15 | 2000-11-02 | Research Foundation Of State University Of New York, The | Cellular matrix system and use thereof |
| ATE424162T1 (de) | 1999-08-06 | 2009-03-15 | Cook Biotech Inc | Rohrförmige transplantatkonstruktion |
| ES2325977T3 (es) | 1999-09-28 | 2009-09-28 | Organogenesis Inc. | Fibrillas de colageno obtenidas por biotecnologia. |
| US6592794B1 (en) | 1999-09-28 | 2003-07-15 | Organogenesis Inc. | Process of making bioengineered collagen fibrils |
| US6482240B1 (en) | 1999-12-07 | 2002-11-19 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Method of making a collagen membrane from porcine skin |
| US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
| DE60009339T2 (de) | 1999-12-22 | 2004-08-19 | Acell, Inc., Cambridge | Zusammensetzung zur gewebsregeneration |
| US6479064B1 (en) | 1999-12-29 | 2002-11-12 | Children's Medical Center Corporation | Culturing different cell populations on a decellularized natural biostructure for organ reconstruction |
| US20020039788A1 (en) | 2000-02-29 | 2002-04-04 | Isseroff Roslyn R. | Corneal epithelial graft composites |
| EP1272204B1 (en) | 2000-04-14 | 2007-06-20 | University of Pittsburgh | Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof |
| US6893812B2 (en) | 2000-05-30 | 2005-05-17 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Three-dimensional ex vivo angiogenesis system |
| DE10026789B4 (de) | 2000-05-31 | 2004-09-02 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Knorpelersatz und Verfahren zu dessen Herstellung |
| ATE308610T1 (de) | 2000-05-31 | 2005-11-15 | Fraunhofer Ges Forschung | Dreidimensionales hautmodell |
| CZ301649B6 (cs) | 2000-06-28 | 2010-05-12 | Ed. Geistlich Soehne Ag Fur Chemische Industrie Incorporated Under The Laws Of Switzerland | Trubice pro regeneraci nervu a zpusob jejich výroby |
| DE10032610C2 (de) | 2000-07-07 | 2003-05-15 | Fischer W Mueller Blasformtech | Verfahren zum Herstellen von Kunststoff-Blasformartikeln |
| HUP0300810A2 (hu) | 2000-07-20 | 2003-08-28 | M.G.V.S. Ltd. | Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása |
| ATE332964T1 (de) | 2000-08-16 | 2006-08-15 | Univ Duke | Mittels gewebetechnologie hergestellte dezellularisierte gegenstände und gewebe |
| EP1315797A2 (en) | 2000-09-06 | 2003-06-04 | Universit Laval | In vitro human angiogenesis model |
| US20020076816A1 (en) | 2000-12-04 | 2002-06-20 | Jianwu Dai | Stem cells and signals developed for use in tissue and organ repair and replacement |
| US6586493B1 (en) | 2001-03-07 | 2003-07-01 | Arizona Board Of Regents Arizona State University | Polysaccharide-based hydrogels and pre-gel blends for the same |
| US7029689B2 (en) | 2001-05-10 | 2006-04-18 | Georgia Tech Research Corporation | Tubular construct for implantation |
| CA2388723C (en) | 2001-06-06 | 2012-10-23 | Becton, Dickinson & Company | Method of providing a substrate with a ready-to-use, uniformly distributed extracellular matrix |
| WO2002102237A2 (en) | 2001-06-15 | 2002-12-27 | The Cleveland Clinic Foundation | Tissue engineered mitral valve chrodae and methods of making and using same |
| JP4426285B2 (ja) | 2001-06-28 | 2010-03-03 | クック・バイオテック・インコーポレーテッド | 腎被膜コラーゲンを含有する移植片プロテーゼ用具 |
| ATE378380T1 (de) | 2001-06-28 | 2007-11-15 | Pv Ind B V | Verfahren zur wiedergewinnung von nativem collagen |
| AU2002323526A1 (en) | 2001-08-31 | 2003-03-18 | Pacgen Cellco Llc | Use of recipient endothelial cells for enhanced vascularization of tissue and tissue-engineered construct transplants |
| DE20115753U1 (de) | 2001-09-14 | 2002-01-10 | Institut für Agrar- und Stadtökologische Projekte an der Humboldt-Universität zu Berlin, 10115 Berlin | Lösliche Kollagene |
| AU2003202261A1 (en) | 2002-01-11 | 2003-07-30 | Purdue Research Foundation | Biomaterial derived from vertebrate liver tissue |
| US8394371B2 (en) | 2002-02-11 | 2013-03-12 | Neocutis Sa | Compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same |
| US20070026518A1 (en) | 2005-03-29 | 2007-02-01 | The Regents Of The University Of California | Controlling stem cell destiny with tunable matrices |
| US20060014284A1 (en) | 2002-03-21 | 2006-01-19 | Thomas Graeve | Biomatrix and method for producting the same |
| CA2482351A1 (en) | 2002-04-12 | 2003-10-23 | Yale University | Vascularized human skin equivalent |
| CN1684589A (zh) | 2002-05-02 | 2005-10-19 | 普渡研究基金会 | 血管化增强的移植构造物 |
| AU2003234317B2 (en) | 2002-05-02 | 2009-04-09 | Purdue Research Foundation | Vascularization enhanced graft constructs |
| WO2003092471A2 (en) | 2002-05-02 | 2003-11-13 | Cook Biotech Incorporated | Cell-seeded extracellular matrix grafts |
| EP1503789A4 (en) | 2002-05-02 | 2006-08-02 | Purdue Research Foundation | IMPROVED VASCULARIZATION BY GRAFT CONSTRUCTIONS |
| AUPS242702A0 (en) | 2002-05-21 | 2002-06-13 | Colltech Australia Limited | Improved method for the extraction and purification of collagen |
| AU2003279730A1 (en) | 2002-09-30 | 2004-04-19 | Fibrogen, Inc. | Dry tissue sealant compositions |
| US20040126405A1 (en) | 2002-12-30 | 2004-07-01 | Scimed Life Systems, Inc. | Engineered scaffolds for promoting growth of cells |
| EP1605862A4 (en) | 2003-02-28 | 2008-09-03 | Fibrogen Inc | COLLAGEN COMPOSITIONS AND BIOMATERIALS |
| WO2005003300A2 (en) | 2003-06-04 | 2005-01-13 | University Of South Carolina | Tissue scaffold having aligned fibrils, apparatus and method for producing same, and methods of using same |
| US20050014181A1 (en) | 2003-06-18 | 2005-01-20 | Galis Zorina S. | Methods and compositions for the assessment of polymer assembly |
| US8741352B2 (en) | 2003-08-25 | 2014-06-03 | Cook Biotech Incorporated | Graft materials containing ECM components, and methods for their manufacture |
| US8043614B2 (en) | 2004-03-09 | 2011-10-25 | Ahlfors Jan-Eric W | Autogenic living scaffolds and living tissue matrices: methods and uses thereof |
| CA2554094A1 (en) | 2004-02-09 | 2005-08-25 | Indiana University Research And Technology Corporation | Isolation, expansion and use of clonogenic endothelial progenitor cells |
| US8337545B2 (en) | 2004-02-09 | 2012-12-25 | Cook Medical Technologies Llc | Woven implantable device |
| WO2005081970A2 (en) | 2004-02-24 | 2005-09-09 | The Curators Of The University Of Missouri | Self-assembling cell aggregates and methods of making engineered tissue using the same |
| US20050260748A1 (en) | 2004-02-27 | 2005-11-24 | Michigan State University | Adult stem cells and uses thereof |
| GB0415080D0 (en) | 2004-07-05 | 2004-08-04 | Ucl Biomedica Plc | Methods for preparing tissue equivalent implants and products thereof |
| WO2006030442A2 (en) | 2004-09-16 | 2006-03-23 | Gamida-Cell Ltd. | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
| WO2006047310A2 (en) | 2004-10-22 | 2006-05-04 | The Board Of Trustees Of The University Of Illinois | Hollow and porous orthopaedic or dental implant that delivers a biological agent |
| WO2006060779A2 (en) | 2004-12-03 | 2006-06-08 | Case Western Reserve University | Novel methods, compositions and devices for inducing neovascularization |
| US20060134072A1 (en) | 2004-12-22 | 2006-06-22 | Pedrozo Hugo A | Self-assembling protein matrix prepared from natural extracellular matrices |
| US8728463B2 (en) | 2005-03-11 | 2014-05-20 | Wake Forest University Health Science | Production of tissue engineered digits and limbs |
| AU2006247228B2 (en) | 2005-05-16 | 2012-04-26 | Purdue Research Foundation | Engineered extracellular matrices control stem cell behavior |
| GB2441098B (en) | 2005-05-16 | 2010-05-26 | Purdue Research Foundation | Engineered extracellular matrices |
| US20100068804A1 (en) | 2005-09-01 | 2010-03-18 | Duke University | Methods of stimulating expansion of hematopoietic stem cells |
| GB0524048D0 (en) | 2005-11-25 | 2006-01-04 | Ucl Biomedica Plc | Bio-artificial materials with tuneable properties |
| US20070190646A1 (en) | 2006-02-10 | 2007-08-16 | The Trustees Of The University Of Pennsylvania | Regulating stem cell differentiation by controlling matrix elasticity |
| US20070269476A1 (en) | 2006-05-16 | 2007-11-22 | Voytik-Harbin Sherry L | Engineered extracellular matrices control stem cell behavior |
| WO2007136634A1 (en) | 2006-05-16 | 2007-11-29 | Purdue Research Foundation | Three dimensional purified collagen matrices |
| US20080026032A1 (en) | 2006-07-27 | 2008-01-31 | Zubery Yuval | Composite implants for promoting bone regeneration and augmentation and methods for their preparation and use |
| CN104623642A (zh) | 2006-10-06 | 2015-05-20 | 人类起源公司 | 天然(端肽)胎盘胶原组合物 |
| JP2010509316A (ja) | 2006-11-09 | 2010-03-25 | ガミダ セル リミテッド | 末梢血管疾患を治療するためのエクスビボ培養された造血細胞の使用 |
| WO2008101100A2 (en) | 2007-02-14 | 2008-08-21 | Indiana University Research And Technology Corporation | Composition for stimulating formation of vascular structures |
| US20100272697A1 (en) | 2007-04-10 | 2010-10-28 | Ali Naji | Pancreatic islet cells composition and methods |
| WO2008131293A2 (en) | 2007-04-19 | 2008-10-30 | Collengin, Inc. | Oriented collagen-based materials, films and methods of making same |
| GB0713079D0 (en) | 2007-07-05 | 2007-08-15 | Ucl Business Plc | biomaterial scaffolds with defined stiffness |
| AU2008331099B2 (en) | 2007-11-26 | 2013-10-24 | Collplant Ltd. | Compositions comprising fibrous polypeptides and polysaccharides |
| US9867905B2 (en) | 2007-12-10 | 2018-01-16 | Purdue Research Foundation | Collagen-based matrices with stem cells |
| JP2011523355A (ja) | 2008-05-07 | 2011-08-11 | ユーシーエル ビジネス ピーエルシー | 生体模倣細胞足場 |
| WO2010054121A2 (en) | 2008-11-07 | 2010-05-14 | Specialized Vascular Technologies, Inc. | Extracellular matrix modulating coatings for medical devices |
| US20120171768A1 (en) | 2009-04-20 | 2012-07-05 | Purdue Research Foundation | Collagen-based matrices for vessel density and size regulation |
| US9744123B2 (en) | 2009-06-30 | 2017-08-29 | Kensey Nash Corporation | Biphasic implant device providing gradient |
| GB0912399D0 (en) | 2009-07-16 | 2009-08-26 | Ucl Business Plc | Polymeric collagen biomaterials |
| US20120115222A1 (en) | 2009-07-16 | 2012-05-10 | Purdue Research Foundation | Composition and method for maintenance, differentiation, and proliferation of stem cells |
| US8652500B2 (en) | 2009-07-22 | 2014-02-18 | Acell, Inc. | Particulate tissue graft with components of differing density and methods of making and using the same |
| BR112012003092A2 (pt) | 2009-08-11 | 2016-11-29 | Univ Johns Hopkins | composições e métodos para implantação de tecido adiposo processado e produtos de tecido adiposo processados. |
| US20120273993A1 (en) | 2009-11-24 | 2012-11-01 | Collplant Ltd. | Method of generating collagen fibers |
| US8475824B2 (en) | 2010-01-26 | 2013-07-02 | Warsaw Orthopedic, Inc. | Resorbable matrix having elongated particles |
| WO2011154686A1 (en) | 2010-06-10 | 2011-12-15 | Ucl Business Plc | Apparatus, kits and methods for the production of biomimetic constructs |
| GB201011476D0 (en) | 2010-07-07 | 2010-08-25 | Ucl Business Plc | Controlled production of biomaterial |
| US20120027732A1 (en) | 2010-07-27 | 2012-02-02 | Voytik-Harbin Sherry L | Thermoreversible collagen |
| TW201247157A (en) | 2011-05-27 | 2012-12-01 | Hon Hai Prec Ind Co Ltd | Object searching system and method, sweeper with the system |
| WO2012167249A2 (en) | 2011-06-02 | 2012-12-06 | Indiana University Research And Technology Corporation | Materials and methods for controlling vasculogenesis from endothelial colony forming cells |
| FR2975922B1 (fr) | 2011-06-06 | 2013-05-31 | Arkema France | Reacteur a plaques avec injection in situ |
| CA2881796A1 (en) | 2012-08-17 | 2014-02-20 | Allosource | Adipose composition systems and methods |
| US20140193477A1 (en) | 2012-10-11 | 2014-07-10 | Emory University | Collagen based materials and uses related thereto |
| EP2951193A4 (en) | 2013-02-01 | 2017-03-01 | Children's Medical Center Corporation | Collagen scaffolds |
| GB201314312D0 (en) | 2013-08-09 | 2013-09-25 | Regentec Ltd | Composition and delivery system |
| US9878071B2 (en) * | 2013-10-16 | 2018-01-30 | Purdue Research Foundation | Collagen compositions and methods of use |
| KR20170070008A (ko) | 2014-08-15 | 2017-06-21 | 더 존스 홉킨스 유니버시티 | 조직 복원용 복합 재료 |
| EP3185922B1 (en) | 2014-08-27 | 2025-04-02 | Purdue Research Foundation | Collagen-based therapeutic delivery systems |
| JP6771567B2 (ja) | 2015-09-10 | 2020-10-21 | シンバイオセルテック・エルエルシー | 幹細胞と膵島細胞を含む新膵島及びそれによる糖尿病の治療 |
| JP7242553B2 (ja) | 2017-01-31 | 2023-03-20 | ジェニフィス，インコーポレイテッド | 基質の調製のための方法及び組成物 |
| WO2019023266A1 (en) * | 2017-07-25 | 2019-01-31 | Purdue Research Foundation | ENCAPSULATION OF COLLAGEN OF CELLS PRODUCING INSULIN |
-
2018
- 2018-01-31 JP JP2019562223A patent/JP7242553B2/ja active Active
- 2018-01-31 CA CA3052266A patent/CA3052266A1/en active Pending
- 2018-01-31 US US16/482,465 patent/US12280176B2/en active Active
- 2018-01-31 CN CN201880019401.8A patent/CN110446500B/zh active Active
- 2018-01-31 ES ES18747153T patent/ES3040675T3/es active Active
- 2018-01-31 EP EP18747153.7A patent/EP3576775B1/en active Active
- 2018-01-31 WO PCT/US2018/016069 patent/WO2018144496A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001511431A (ja) | 1997-07-28 | 2001-08-14 | フィブロジェン， インコーポレイテッド | Ｉ型およびｉｉｉ型コラーゲン接着剤組成物 |
| US20080268052A1 (en) | 2006-09-21 | 2008-10-30 | Voytik-Harbin Sherry L | Collagen preparation and method of isolation |
| US20120297550A1 (en) | 2007-06-12 | 2012-11-29 | Musculoskeletal Transplant Foundation | Process for sterilizing acellular soft tissue with irradiation |
| JP2011525197A (ja) | 2009-07-27 | 2011-09-15 | 國立成功大學 | 高純度コラーゲンの調製 |
Non-Patent Citations (3)
| Title |
|---|
| Bailey, J. L. et al.，Collagen oligomers modulate physical and biological properties of three-dimensional self-assembled matrices.，Biopolymers，2011年，95(2)，77-93 |
| Kreger, S. T. et al.，Polymerization and matrix physical properties as important design considerations for soluble collagen formulations.，Biopolymers，2010年，93(8)，690-707 |
| Rucha Joshi，Designer collagen-fibril biograft materials for tunable molecular delivery，Purdue e-Pubs，2016年，インターネット<https://docs.lib.purdue.edu/cgi/viewcontent.cgi?article=2434&context=open_access_dissertations>[検索日：令和3年11月15日] |
Also Published As
| Publication number | Publication date |
|---|---|
| US12280176B2 (en) | 2025-04-22 |
| CA3052266A1 (en) | 2018-08-09 |
| EP3576775A1 (en) | 2019-12-11 |
| CN110446500A (zh) | 2019-11-12 |
| EP3576775A4 (en) | 2020-11-25 |
| EP3576775B1 (en) | 2025-06-25 |
| WO2018144496A1 (en) | 2018-08-09 |
| US20200246507A1 (en) | 2020-08-06 |
| ES3040675T3 (en) | 2025-11-04 |
| JP2020505474A (ja) | 2020-02-20 |
| CN110446500B (zh) | 2024-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7242553B2 (ja) | 基質の調製のための方法及び組成物 | |
| Zhang et al. | A highly elastic and rapidly crosslinkable elastin‐like polypeptide‐based hydrogel for biomedical applications | |
| Lee et al. | Human hair keratin and its-based biomaterials for biomedical applications | |
| King et al. | The use of injectable forms of fibrin and fibronectin to support axonal ingrowth after spinal cord injury | |
| Wei et al. | Hyaluronic acid hydrogels with IKVAV peptides for tissue repair and axonal regeneration in an injured rat brain | |
| US9688741B2 (en) | Elastic hydrogel | |
| EP4023240A1 (en) | Purified amphiphilic peptide compositions and uses thereof | |
| US9889086B2 (en) | Bioadhesive and injectable hydrogel | |
| Zheng et al. | 3D-printed HA15-loaded β-tricalcium phosphate/poly (lactic-co-glycolic acid) bone tissue scaffold promotes bone regeneration in rabbit radial defects | |
| Yang et al. | Using type III recombinant human collagen to construct a series of highly porous scaffolds for tissue regeneration | |
| Albu et al. | Collagen-based drug delivery systems for tissue engineering | |
| CN105246520A (zh) | 可缩放的三维弹性构建体制造 | |
| Ramakrishnan et al. | Silk fibroin-based bioengineered scaffold for enabling hemostasis and skin regeneration of critical-size full-thickness heat-induced burn wounds | |
| CN104902937A (zh) | 一种将胶原和纤维蛋白混合的组织封闭剂及其制备方法 | |
| EP3511029B1 (en) | Dermal layer for grafting having improved graft survival rate and method for producing same | |
| Yuan et al. | Platelet-rich plasma gel-loaded collagen/chitosan composite film accelerated rat sciatic nerve injury repair | |
| Liu et al. | Self-assembled nanofibrous marine collagen matrix accelerates healing of full-thickness wounds | |
| Liu et al. | Finite element analysis of | |
| US10723783B2 (en) | Polypeptide compositions and methods of using the same | |
| CN108379650A (zh) | 一种新型促创面愈合生物胶及其应用 | |
| Huang et al. | Biological activity of self-assembled peptide hydrogel scaffold RADA-RGD and its experimental study of BMP-2 release in vitro | |
| KR20230022392A (ko) | 유무기 복합 하이드로겔 제조용 조성물 및 이를 포함하는 유무기 복합 하이드로겔 제조용 키트 | |
| WO2017205740A1 (en) | Process for preparing tissue regeneration matrix | |
| Zhang et al. | Exploration of 2D and 2.5 D conformational designs applied on epoxide/collagen-based integrative biointerfaces with device/tissue heterogeneous affinity | |
| Cano Salazar et al. | Nanocomposites Comprise of Collagen and Acrylate-Derived Polymers for Biomedical Applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210127 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210127 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20211115 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211119 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220217 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220418 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220512 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220512 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220825 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221118 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20221219 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20221220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230117 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230207 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230308 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7242553 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |